MedTrace Logo

IAT-MeVO Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial

NCT07336927 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 614

Last updated 2026-01-15

No results posted yet for this study

Summary

IAT-MeVO is an international, multicenter, prospective, randomised, open-label, blinded end-point assessed (PROBE) trial, to evaluate the efficacy and safety of endovascular therapy (EVT) \[intra-arterial thrombolysis (IAT)-based\] versus best medical management (BMT) in patients with acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) who are ineligible for intravenous thrombolysis (IV) within 24 h of onset.

Conditions

  • Acute Ischemic Stroke Due to Medium-vessel-occlusion

Interventions

PROCEDURE

Endovascular Treatment

Patients will receive IAT-based EVT in addition to medical treatment. IAT with TNK will be performed first. If adequate dosing fails to achieve reperfusion, the surgical team may evaluate the need for aspiration or stent retriever thrombectomy. For second-order branches (M2/A1/P1 segments), the number of retrieval attempts must not exceed three; for third-order branches (M3/A2/P2 and beyond), no more than two attempts are allowed. \*Arterial thrombolysis protocol: Dose: 0.125 mg/kg body weight, maximum 12.5 mg \*No restrictions will be placed on the choice of aspiration catheters or stent retrievers used in this study.

Sponsors & Collaborators

  • West China Hospital

    collaborator OTHER

  • Mianyang Central Hospital

    collaborator OTHER

  • Chengdu First People's Hospital

    collaborator OTHER

  • Sichuan Provincial People's Hospital

    collaborator OTHER

  • Deyang People's Hospital

    collaborator OTHER

  • Suining Central Hospital

    collaborator OTHER

  • The Second People's Hospital of Chengdu

    collaborator OTHER

  • Bo Wu

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07336927 on ClinicalTrials.gov